ResearchHLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor1 Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, South-1, West-16, Chuo-ku, Sapporo, 060-8543, Japan 2 Department of Pathology, Sapporo Medical University School of Medicine, South-1, West-17, Chuo-ku, Sapporo, 060-8556, Japan
Journal of Translational Medicine 2009, 7:44doi:10.1186/1479-5876-7-44
Additional filesAdditional file 1: Sequences and binding affinities of PBF-derived peptides with HLA-A*0201 binding motif. *Binding score was determined by BIMAS HLA Peptide Binding Predictions. †The affinity of each peptide (50 μg/ml) was evaluated by a HLA class I stabilization assay. Format: XLS Size: 17KB Download file This file can be viewed with: Microsoft Excel Viewer Additional file 2: Clinical picture and frequency of anti-PBF A2.2 peptide CTLs in PBMC of patients with osteosarcoma. P: primary tumor, M: metastatic tumor. †Frequency of anti-PBF A2.2 CTLs among CD8+ cells. ‡Parentheses indicate that the tumor had been resected at the time of blood sampling. §Magnetically separated CD8+ cells. Irradiated peptide-pulsed CD8- cells were used as stimulator. Format: XLS Size: 37KB Download file This file can be viewed with: Microsoft Excel Viewer |





on Google Scholar









author email
corresponding author email